Overview
SERCA2a is the dominant Ca²⁺ reuptake pump of the cardiac sarcoplasmic reticulum (SR) and the molecular engine of diastolic Ca²⁺ removal. Each catalytic cycle couples the hydrolysis of one ATP to the active transport of two Ca²⁺ ions from the cytosol into the SR lumen against a steep electrochemical gradient, restoring diastolic [Ca²⁺]i to ~100 nM.
SERCA2a is responsible for approximately 70% of cytosolic Ca²⁺ removal following each systole in human ventricular myocytes. By refilling the SR Ca²⁺ store, it simultaneously: (1) lowers cytosolic [Ca²⁺] → enables muscle relaxation (lusitropy); and (2) refills the SR → provides Ca²⁺ available for the next contraction cycle.
SERCA2a function is tonically inhibited by phospholamban (PLN) — a 52 aa micropeptide that is the principal physiological brake on pump activity. This PLN–SERCA2a binary interaction is a central regulatory node of sympathetic heart rate and contractility.
Heart failure target: SERCA2a expression and activity are reduced 30–50% in HFrEF, impairing Ca²⁺ reuptake, slowing relaxation, and reducing SR Ca²⁺ load. AAV1-SERCA2a gene therapy (CUPID trial) showed promising phase 2a results but did not demonstrate benefit in the definitive phase 2b — ongoing investigation into vector efficiency and patient selection continues.
Structure
P-type ATPase Architecture
| Domain | Location | Function |
|---|---|---|
| Actuator domain (A) | Cytoplasmic, N-terminal | Couples ATP hydrolysis to TM motion; contains invariant Glu-239 |
| Nucleotide-binding domain (N) | Cytoplasmic, central | ATP binding; largest cytoplasmic domain |
| Phosphorylation domain (P) | Cytoplasmic, between TM4–5 | Catalytic Asp-351; transiently phosphorylated during E1P→E2P cycle |
| TM1–TM10 bundle | Membrane | Ca²⁺ binding sites I (Asn-768/Glu-771/Thr-799/Asp-800) and II (Glu-309/Asn-796/Asp-800/Glu-908); conformational change drives Ca²⁺ translocation |
SERCA Isoforms
| Gene | Isoform | Predominant tissue |
|---|---|---|
ATP2A1 | SERCA1a/1b | Fast-twitch skeletal muscle |
ATP2A2 | SERCA2a | Cardiac and slow-twitch skeletal muscle |
ATP2A2 | SERCA2b | Ubiquitous (longer C-terminus; higher Ca²⁺ affinity; not regulated by PLN) |
ATP2A3 | SERCA3 | Platelets, immune cells, epithelium |
Mechanism
Post-Albers Catalytic Cycle and PLN Regulation
── SERCA2a Post-Albers cycle ─────────────────────────────
E1 state (cytoplasmic face open, high Ca²⁺ affinity)
Km ~0.2 µM (free SERCA2a) / ~0.6 µM (PLN-inhibited)
↓ Binds 2 Ca²⁺ at cytoplasmic sites I + II
↓ ATP binds N domain
E1P · 2Ca²⁺ (phosphoenzyme)
γ-phosphate transfers from ATP to Asp-351 (P domain)
↓
E2P (occluded / low-affinity lumen-facing)
TM helices rearrange → Ca²⁺ occluded then released into SR lumen
[Ca²⁺]SR lumen: free ~1–2 mM, bound ~30 mM (CASQ2)
↓
E2 (Pi released, pump resets)
Returns to E1 conformation → next cycle
── PLN inhibition and relief ──────────────────────────────
Unphospho-PLN:
TM helix engages SERCA2a TM2/6/9 → stabilizes E2 state
Cytoplasmic domain Ia contacts actuator domain
Net: Km for Ca²⁺ 0.2 → 0.6 µM (~2x slower pump at 100 nM [Ca²⁺])
PKA → PLN Ser16-P (β1-AR sympathetic stimulation):
Negative charge on PLN-Ia → electrostatic repulsion
PLN disengages from SERCA2a
Km returns to 0.2 µM → FASTER Ca²⁺ reuptake
→ FASTER relaxation (lusitropy)
→ HIGHER SR Ca²⁺ load → LARGER Ca²⁺ transient next beat (inotropy)
Fractional Ca²⁺ Removal Per Beat
| Pathway | Fractional removal (human ventricle) |
|---|---|
| SERCA2a (SR uptake) | ~70% |
| NCX1 (sarcolemmal extrusion) | ~28% |
| Sarcolemmal Ca²⁺-ATPase (PMCA) | ~1% |
| Mitochondrial uniporter | ~1% |
The predominance of SERCA2a (~70%) in human myocardium means most of the Ca²⁺ released each beat is recaptured into the SR, maintaining SR Ca²⁺ content relatively constant beat-to-beat. This contrasts with rabbit myocytes where NCX1 contributes ~50% — an important species difference in Ca²⁺ cycling.
Pathology
| Disease | SERCA2a mechanism |
|---|---|
| Heart failure with reduced EF (HFrEF) | SERCA2a expression and activity reduced 30–50%; Ca²⁺ reuptake slower; diastolic [Ca²⁺] elevated; SR Ca²⁺ load depleted → reduced systolic Ca²⁺ transient → reduced contractility + impaired relaxation. One of the most consistent molecular hallmarks of HFrEF. |
| Diastolic dysfunction (HFpEF) | Impaired SERCA2a kinetics prolong Ca²⁺ transient decay → slower IVRT → elevated filling pressures. PLN hyper-inhibition and reduced PLN phosphorylation are contributing mechanisms. |
| AAV1-SERCA2a gene therapy (CUPID) | Intracoronary delivery of AAV1-SERCA2a in HFrEF patients; improved NYHA class and HF hospitalizations in phase 2a (n=39); phase 2b (CUPID-2, n=250) showed no significant benefit — likely due to insufficient gene delivery; optimization of vectors and dosing ongoing. |
| Darier disease | Autosomal dominant ATP2A2 mutations primarily affect the ubiquitous SERCA2b isoform → keratinocyte Ca²⁺ dysregulation → acantholytic skin disorder. Cardiac SERCA2a isoform may be mildly affected in some patients. |
| Ischemia | ATP depletion → SERCA2a stops pumping → cytosolic Ca²⁺ rises → Ca²⁺ overload → myofibril hypercontraction → cell death. NCX reverse mode also contributes (see NCX1 entry). |
Connections
- expressed-byCardiomyocyte — SERCA2a is the dominant cardiac SR pump, localized to longitudinal SR membrane; handles ~70% of Ca²⁺ removal per beat
- modulated-byPhospholamban — tonic inhibitor; dephospho-PLN shifts SERCA2a Km from 0.2 to 0.6 µM; phospho-PLN (by PKA/CaMKII) relieves inhibition
- modulated-byβ1-adrenergic receptor → PKA → PLN Ser16 phosphorylation → SERCA2a disinhibition → lusitropy + increased SR loading
- refillsRyR2 SR Ca²⁺ store — SERCA2a replenishes the SR after each CICR cycle; the ratio of SERCA2a activity to RyR2 leak determines SR Ca²⁺ content
- competes-withNCX1 — competing Ca²⁺ removal pathways; SERCA2a recaptures Ca²⁺ into SR; NCX1 extrudes Ca²⁺ extracellularly; balance determines SR Ca²⁺ load
References
- MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4(7):566–77. PubMed 12838339.
- Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205. PubMed 11805843.
- Periasamy M, Bhargava V. Sarcoplasmic reticulum calcium ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res. 1999;42(3):583–97. PubMed 10533672.
- Jessup M, Greenberg B, Mancini D, et al. CUPID: Calcium upregulation by percutaneous administration of gene therapy in cardiac disease. Circulation. 2011;124(3):304–13. PubMed 21709064.